Actemra Looks Promising in Scleroderma

May 17, 2015 | News, Scleroderma

Actemra Looks Promising in Scleroderma

Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study by Christopher P. Denton, MBBS, of University College Londo.

At 24 weeks, a numerically favorable response was seen on modified Rodnan skin scores and lung fibrosis among patients randomized to tocilizumab compared with those receiving placebo. The study is now continuing with a phase III trial that includes a greater number of patients.

Read the entire article at>>

FESCA news & eventsnews & events

Share This